Papillomavirus infections are caused by human papillomaviruses (HPV), a diverse group of DNA viruses that infect epithelial tissues. While many HPV infections are benign and resolve spontaneously, persistent infections with high-risk HPV types can lead to various cancers. HPV is primarily transmitted through direct skin-to-skin contact, and sexual activity is a common mode of transmission. Low-risk HPV types can cause genital warts, while high-risk types are associated with cervical, anal, penile, and oropharyngeal cancers. Cervical cancer, in particular, has a strong association with high-risk HPV infections, prompting the development of HPV vaccines. These vaccines, such as Gardasil and Cervarix, target specific HPV types and have been effective in preventing infection and related cancers. Screening programs, such as Pap smears and HPV testing, aid in early detection and management of HPV-associated diseases. Public health initiatives aim to increase HPV vaccination coverage, raise awareness, and reduce the burden of HPV-related cancers globally. Ongoing research focuses on improving vaccination strategies, understanding the natural history of HPV infections, and developing novel therapeutic interventions.
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia